Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Gynecol Oncol. 2010 May;117(2):183-8. doi: 10.1016/j.ygyno.2009.11.029. Epub 2010 Jan 6.
Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples.
One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed.
Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p<0.001) and further during and after first-line chemotherapy (median serum levels 21 and 15 kU/L, p<0.001). No intermarker correlation was observed.
CAIX is upregulated in ovarian cancer and serum CAIX could be a marker to stratify patients for therapy response. However, CAIX serum levels did not change significantly during first-line therapy and were not prognostically relevant. Based on the findings of the current study, CAIX cannot be recommended for therapy monitoring in this context.
碳酸酐酶 IX（CAIX）主要参与维持细胞外 pH 值。它在多种肿瘤中过度表达，包括卵巢癌。为了评估血清 CAIX 对卵巢癌治疗反应的潜在预后和预测作用，我们分析了纵向血清样本。
分析了 37 名原发性上皮性卵巢癌患者的 148 份血清样本。这些样本是在 4 个时间点前瞻性采集的：（1）根治性手术前，（2）手术后和铂类/紫杉醇化疗前，（3）化疗期间，（4）化疗后。通过 ELISA 定量检测血清 CAIX，并通过免疫组化验证肿瘤组织中的表达。分析与反应和临床结局以及肿瘤标志物 CA-125 的相关性。
血清 CAIX 浓度范围为 30 至 1687 pg/mL，在一线治疗期间无明显变化（手术前后中位数水平分别为 204 和 198 pg/mL，化疗期间和化疗后分别为 175 和 181 pg/mL）。血清 CAIX 与无进展生存期或总生存期之间无相关性。手术后 CA-125 显著下降（手术前后中位数血清水平分别为 413 和 84 kU/L，p<0.001），并在一线化疗期间和之后进一步下降（中位数血清水平分别为 21 和 15 kU/L，p<0.001）。未观察到标志物之间的相关性。
CAIX 在卵巢癌中上调，血清 CAIX 可作为预测治疗反应的标志物。然而，在一线治疗期间，CAIX 血清水平没有明显变化，与预后无关。基于本研究的发现，CAIX 不能在该情况下推荐用于治疗监测。
